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MaBACKGROUND Cardiac electrical conduction delays and blocks cause rhythm disturbances such as complete heart block,
which can be fatal. Standard of care relies on electronic devices to artiﬁcially restore synchrony. We sought to create a new
modality for treating these disorders by engineering electrical conduction tracts designed to propagate electrical impulses.
OBJECTIVES This study sought to create a new approach for treating cardiac conduction disorders by using engineered
electrical conduction tracts (EECTs).
METHODS Paramagnetic beads were conjugated with an antibody to gamma-sarcoglycan, a cardiomyocyte cell
surface antigen, and mixed with freshly isolated neonatal rat ventricular cardiomyocytes. A magnetic ﬁeld was used
to pattern a linear EECT.
RESULTS In an in vitro model of conduction block, the EECT was patterned so that it connected 2 independently
beating neonatal rat ventricular cardiomyocyte monolayers; it achieved coordinated electrical activity, with action
potentials propagating from 1 region to the other via EECT. Spiking the EECT with heart-derived stromal cells yielded
stable structures with highly reproducible conduction velocities. Transplantation of EECTs in vivo restored atrioven-
tricular conduction in a rat model of complete heart block.
CONCLUSIONS An EECT can re-establish electrical conduction in the heart. This novel approach could, in principle, be
used not only to treat cardiac arrhythmias but also to repair other organs. (J Am Coll Cardiol 2014;64:2575–85)
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ABBR EV I A T I ON S
AND ACRONYMS
AV = atrioventricular
CDCs = cardiosphere-derived
cells
CV = conduction velocity
Cx = connexin
EDAC = 1-ethyl-3-
(3-dimethylaminopropyl)
carbodiimide
EECT = engineered electrical
conduction tract
EECT-C = cardiosphere-
derived cell-enriched
engineered electrical
conduction tract
EGMs = electrograms
GFP = green ﬂuorescent
protein
NRVMs = neonatal rat
ventricular myocytes
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2576progressive decline in pump function (4,5).
Ablation destroys living heart tissue and, in
ventricular tachycardia, is associated with
signiﬁcant morbidity and mortality (6–8).SEE PAGE 2586Our goal was to create a new approach to
treating such disorders by using engineered
electrical conduction tracts (EECTs) designed
to bridge or bypass zones of impaired con-
duction. We report a highly generalizable
means of creating these EECTs by using mag-
netic patterning to orient cells conjugated to
paramagnetic microbeads. As proof of con-
cept, we showed that EECTs can re-establish
electrical conduction between disconnected
regions of 2-dimensional cardiac tissue and
in an animal model of complete heart block.
METHODSFORMATION OF CELL-TARGETED PARAMAGNETIC BEADS.
Paramagnetic ﬂuorescent microspheres (8 mm in
diameter; Bangs Laboratories, Inc., Fishers, Indiana)
were conjugated with gamma-sarcoglycan antibody
(200 mg; Santa Cruz Biotechnology, Dallas, Texas) or
with CD105 antibody (200 mg; R&D Technologies,
North Kingstown, Rhode Island) by using the PolyLink
Protein Coupling Kit (Bangs Laboratories) according
to the manufacturer’s instructions. In brief, carboxyl-
modiﬁed polymer-based microspheres were resus-
pended in PolyLink coupling buffer and activated
by addition of 1-ethyl-3-(3-dimethylaminopropyl)car-
bodiimide (EDAC). Covalent binding of the speciﬁc
antibody to the surface of the activated microspheres
was achieved by incubating 200 mg of either gamma-
sarcoglycan or CD105 antibodies at room tempera-
ture for 2 h. Antibody-coated microspheres were
resuspended in PolyLink Wash/Storage buffer and
stored at 4C for subsequent experiments.
CARDIOMYOCYTE ISOLATION, CULTURE, AND
CONJUGATION. Neonatal rat ventricular myocytes
(NRVMs) were isolated from 1- to 2-day-old pups as
described (9). We created a 2-dimensional conduction
block model by plating NRVMs in a culture plate, then
scraping along the middle of the monolayer. Com-
plete conduction block was conﬁrmed 24 h after me-
chanical interruption by verifying asynchronous
beating of the 2 independent monolayers. Freshly
isolated NRVMs (2  106) were incubated in suspen-
sion with gamma-sarcoglycan antibody–coated para-
magnetic microspheres for 4 h at room temperature
by using a 1:1 ratio of cells to microspheres. The newlyformed NRVM–microsphere complexes were subse-
quently used for EECT construction.
CARDIOSPHERE-DERIVED CELL CULTURE AND
CONJUGATION. Human cardiosphere-derived cells
(CDCs) were isolated from heart biopsy specimens
and cultured as described (10). CDCs were incubated
in suspension with CD105 antibody–coated micro-
spheres for 4 h at room temperature by using a 1:1
ratio of cells to microspheres. The newly formed CDC–
microsphere complexes were used for construction of
modiﬁed EECT (cardiosphere-derived cell–enriched
engineered electrical conduction tracts [EECT-C]).
CONSTRUCTION OF EECT IN SITU WITH MAGNETIC
FIELD. To re-establish conduction between the 2
halves of the interrupted NRVM monolayer, an
EECT was created by exposing NRVM–microsphere
complexes (2  106 cells in a 1:1 ratio of cells to mi-
crospheres) to a linear magnetic ﬁeld aligned per-
pendicularly to the axis of interruption. After 12 h,
the cells were removed from the magnetic ﬁeld, and
the culture plate was returned to the incubator
(Online Figure 1). To enhance the physical integrity of
the EECT, the NRVM–microsphere complexes were
mixed with the CDC–microsphere complexes and
plated over a linear magnetic ﬁeld to create EECT-C.
For in vivo transplantation, NRVM–microsphere com-
plexes were plated in an ultralow attachment plate
(Corning Life Sciences, Tewksbury, Massachusetts)
and were then exposed for 12 h in the incubator to
a linear magnet placed underneath the plate. Non-
adherent EECTs were created by exposing the NRVM–
microsphere complexes (5  106 NRVMs in a 1:1 cell
to microsphere ratio) to the magnetic ﬁeld.
HIGH-RESOLUTION OPTICAL MAPPING. Action poten-
tial propagations were recorded on a 469-photodiode
array system (WuTech Instruments, Gaithersburg,
Maryland) by using a voltage-sensitive dye. Cells
were incubated with di-4-ANEPPS (50 mM; Invitrogen
Corporation, Carlsbad, California) for 2 min at 37C,
followed by dye washout. To prevent motion arti-
facts, recordings were obtained at room temperature
in Caþ2-free Tyrode’s solution containing blebbistatin
(10 mM; Sigma-Aldrich Co., St. Louis, Missouri). Action
potential duration and conduction velocity (CV)
across the NRVM monolayers and the EECT were
analyzed with NeuroPlex software (RedShirtImaging,
L.L.C., Decatur, Georgia).
IMMUNOMICROSCOPY AND CONFOCAL MICROSCOPY.
For immunohistochemistry, EECTs were ﬁxed over-
night with 4% paraformaldehyde, permeabilized,
and blocked with Dako protein block solution
(Dako, Carpinteria, California) containing 1% saponin
FIGURE 1 Paramagnetic Bead Conjugation With Cell-Speciﬁc Antibodies
(A, top) Conjugation of green ﬂuorescent microspheres with gamma-sarcoglycan antibody
(red ﬂuorescence) after activation of the beads’ surface carboxyl groups by carbodiimide
(1-ethyl-3-dimethylaminopropyl carbodiimide [EDAC]). (A, bottom) In the absence of
EDAC, no antibody conjugation was seen. (B) Schematic representation of conjugation of
neonatal rat ventricular myocytes (NRVMs) with gamma-sarcoglycan antibody–coated
microspheres.
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2577(Sigma-Aldrich) for 1.5 h. Immunostaining was
performed with primary antibodies against the
following molecules: connexin (Cx) 43 (rabbit, 1:200;
Abcam plc, Cambridge, Massachusetts) and sarco-
meric alpha-actinin (mouse, 1:400; Sigma-Aldrich).
Nuclear staining was performed with 40,6-diamidino-
2-phenylindole, and microspheres were identiﬁed by
their inherent green ﬂuorescence. Incubation of sec-
ondary antibodies conjugated to Cy5 (1:400; Abcam)
or Texas Red (1:400, Abcam) was performed at room
temperature. Images were obtained by using a con-
focal microscope (TCS SP5 X, Leica Microsystems,
Wetzlar, Germany).
To demonstrate in vivo structural integration, rats
were transplanted with EECT-C transduced before
EECT-C construction with an adenovirus-encoding
green ﬂuorescent protein (GFP). Hearts were har-
vested 72 h after transplantation, washed with
phosphate-buffered saline, and ﬁxed with 4% para-
formaldehyde. After overnight incubation with 15%
sucrose, hearts were preserved in optimum cutting
temperature for cryosectioning. Slides were per-
meabilized and blocked with Dako protein block
solution (Dako) for 1.5 h. Immunostaining was per-
formed with the following primary antibodies: Cx43
(rabbit, 1:100; Abcam), sarcomeric alpha-actinin
(mouse, 1:100; Sigma-Aldrich), and GFP (goat, 1:50;
Abcam). Nuclei were stained with 40,6-diamidino-
2-phenylindole, and paramagnetic spheres were
identiﬁed by their inherent green ﬂuorescence. In-
cubation with Alexa Fluor 488 donkey anti-goat
immunoglobulin G, Alexa Fluor 568 goat anti-mouse
immunoglobulin G, or Alexa Fluor 647 goat anti-
rabbit immunoglobulin G (1:400, Life Technologies,
Grand Island, New York) secondary antibodies (Life
Technologies) at 1:400 was performed at room tem-
perature. Images were obtained by using a confocal
microscope (TCS SP5 X, Leica Microsystems).
SCANNING ELECTRON MICROSCOPY. Scanning
electron microscopy was used to visualize the
morphological details of the EECT 3-dimensional
structure. Samples were ﬁxed with 2% glutaralde-
hyde in 0.1 M of sodium cacodylate (pH 7.2) for 1 h,
then dehydrated by using progressive ethanol con-
centrations (35%, 50%, 70%, 80%, 95%, and 100%) for
10 min each and dried in hexamethyldisilazane
(Sigma-Aldrich). Scaffolds were sputter-coated with
gold and images were captured with a LEO-982
scanning electron microscope (LEO Corporation,
Oberkochen, Germany).
IN VIVO TRANSPLANTATION OF ECCT-C. Adult
Sprague Dawley rats (w220 g) were anesthetized by
using isoﬂurane (4% induction, 1.5% maintenance),intubated, and mechanically ventilated. A left thora-
cotomy was performed to expose the heart and the
AV groove for direct visualization. Upon removal of
the pericardium, a pre-formed EECT-C was laid on
top of the heart, connecting the epicardial surfaces of
the right atrium and the right ventricle. The proximal
and distal ends of the EECT-C were afﬁxed to the
right atrium and right ventricle with ﬁbrin glue;
no additional pretreatment was performed at the
attachment points. After conﬁrming the mechanical
stability of the implanted EECT-C, the chest was
closed. Animals were reanesthetized 3 days later
for in vivo surface electrocardiograms, followed
by euthanasia and heart harvest. Given the rapid
FIGURE 2 EECT Ge
NRVM monolayer
A
B
C
(A) Schematic repres
electrical conduction
scopic image of EEC
(10) images. (C) Th
whole-cell calcium t
mation was reproduc
tion). See accompan
Cingolani et al. J A C C V O L . 6 4 , N O . 2 4 , 2 0 1 4
Engineered Conduction Tract Restores Conduction Block D E C E M B E R 2 3 , 2 0 1 4 : 2 5 7 5 – 8 5
2578turnover of Cxs (11,12), the 3-day time point was
chosen to allow the EECT-C to be stably engrafted and
electrically coupled with the heart, while minimizing
rejection of the donor tissue construct. Harvested
whole hearts were mounted on a retrograde Langen-
dorff perfusion system for recording of surface elec-
trograms (EGMs) through epicardial electrodes
connected to a digital recording system (ADInstru-
ments, Colorado Springs, Colorado). Preparations that
exhibited viability and persistent attachment of the
EECT-C were used for analysis.
To assess conduction through the EECT-C, the AV
node was blocked pharmacologically by adding
methacholine (10 mg/ml) to the perfusate. To assay
AV conduction, the right atrium or right ventricle
was paced through epicardial platinum electrodesneration With NRVMs and Paramagnetic Microspheres
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entation of the experimental design used to create an engineered
tract (EECT) to bridge interrupted NRVM monolayers. (B) Macro-
T in suspension with transmitted light (10) and green ﬂuorescent
ree-dimensional (3D) reconstruction of EECT exhibiting spontaneous
ransients, revealed with the Ca2þ-sensitive dye, Rhod-2. EECT for-
ed 20 times from 7 independent NRVM isolations (2 liters per isola-
ying Online Video 1. Abbreviation as in Figure 1.connected to an isolated pulse stimulator (A-M Sys-
tems, Sequim, Washington). Animals were subjected
to sham operation (no EECT-C) or –EECT-C trans-
plantation. Investigators were not blinded to the
group allocation. All animal experiments were per-
formed in compliance with the Cedars-Sinai Institu-
tional Animal Care and Use Committee guidelines.
STATISTICAL ANALYSIS. Statistical signiﬁcance was
calculated by using 2-way analysis of variance or the
Student t test when appropriate. Unless speciﬁed
otherwise, all data are presented as mean  SEM. A
p value <0.05 was considered statistically signiﬁcant.
RESULTS
CREATION OF AN EECT. The study concept was to
form a complex of cardiomyocytes with paramagnetic
beads whose surface is covalently conjugated to a
cardiomyocyte-speciﬁc antibody. Afﬁnity binding of
cardiomyocytes to the beads enables patterning of
the complex into a deﬁned structure by attracting the
beads with a magnetic ﬁeld. Paramagnetic beads 8 mm
in diameter were activated by EDAC, forming cova-
lent bonds between the free carboxyl groups on the
beads’ surfaces and the amide groups on EDAC
(Figure 1A). Primary antibodies were then conjugated
to the activated microspheres via peptide bonds be-
tween amino-terminal groups of the antibody and
carboxyl groups on the microsphere surface. This
antibody–microsphere conjugation step depends on
the catalytic activity of the EDAC; in its absence,
nonspeciﬁc primary antibody binding to the beads
is undetectable (Figure 1B). The microspheres are
manufactured to emit green ﬂuorescence for detec-
tion under ﬂuorescence microscopy.
An ideal cell substrate for EECT constructs should
have high cell–cell electrical coupling within the
EECT and at the ends where the EECT contacts the
host tissue. In addition, the cell substrate should be
terminally differentiated so that the EECT retains its
conduction properties and shape. For proof of
concept, NRVMs satisfy these criteria and thus were
chosen as the EECT cell substrate. A number of car-
diomyocyte cell surface antigens were tested for their
ability to bind to NRVMs, including integrins (alpha
and beta), cadherins (N, E, and I), Cx43 and Cx40,
and sarcoglycans. Among them, gamma-sarcoglycan–
conjugated microspheres exhibited the highest bind-
ing efﬁciency and speciﬁcity for NRVMs. Sarcoglycans
are integral membrane proteins connecting the
contractile apparatus to the extracellular matrix
(13–15). Placing a linear magnet underneath a sus-
pension of the NRVM–microsphere complex formed
an EECT (Figures 2A and 2B). Within 24 h, the
FIGURE 3 Restoration of Conduction in a 2-Dimensional Model of Conduction Block
(A) Optical mapping recordings demonstrate independent activation of interrupted NRVM
monolayers. (B) Restoration of conduction block with simultaneous activation of the 2
NRVM monolayers after EECT implantation. (C) Implantation of EECT parallel to NRVM
monolayers results in asynchronous activation of the 2 NRVM monolayers. Experiments
were reproduced 4 times from 3 independent NRVM isolation procedures (2 liters per
isolation). Abbreviations as in Figures 1 and 2.
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2579EECT demonstrated rhythmic, syncytial contractions
(Online Video 1), indicating that cell–cell electrical
coupling was established within the spontaneously
active construct (16). Global electrical coupling in the
EECT is further demonstrated in Figure 2C, which il-
lustrates spontaneous intracellular Ca2þ transients
measured from a 1-mm2 area of the EECT.
EECT BRIDGES CONDUCTION BETWEEN 2 MONO-
LAYERS OF NRVMS. To test if the EECT could relay
electrical signals, we created an in vitro model of
conduction block by mechanically disrupting the
NRVM monolayers, thus creating 2 independently
beating halves (Figure 3A). To re-establish conduc-
tion, EECTs were formed in situ by placing a magnet
perpendicular to the axis of interruption (Figure 3B).
Within 1 day of EECT formation, the 2 NRVM islands
beat in tandem, and the action potentials propagated
from 1 island to the other via EECT, with a mean CV
of 18  4 cm/s. Action potential morphology and
action potential duration at 90% of repolarization
were similar in the EECT (443  5 ms) and the adjacent
monolayers (439  12 ms; p ¼ NS). NRVMs cultured as
monolayers exhibited occasional spontaneous con-
tractions (17), accounting for the irregular beating
shown in Figure 3B. To control for nonspeciﬁc bridging
of the 2 NRVM islands, EECTs were formed parallel to
the axis of the monolayer interruption (Figure 3C). No
synchronous beating occurred between the 2 NRVM
islands, indicating that the bridging of electrical con-
duction by EECTs is speciﬁc, occurring only when
EECT termini physically contact the disconnected
tissues.
THE ADDITION OF CARDIAC STROMAL CELLS AUGMENTS
CELL VIABILITY AND ELECTRICAL CONDUCTION
PROPERTIES OF THE EECT. The EECT used in Figure 2
was composed of NRVMs and beads only. Although
capable of bridging a conduction gap (Figure 3), the
structure was fragile, which gave rise to large SDs in
EECT conduction velocities. We thus examined if
admixing the NRVMs with another cell type might
stabilize the structures. Antibody-mediated cell
attachment to paramagnetic microspheres allows
incorporation of different cell types by using cell type–
speciﬁc antibodies. CDCs are CD105þ stromal cells
derived from myocardial biopsy specimens (10) that
electrically couple to and exert antiapoptotic effects on
cardiomyocytes (10,18). In the native heart, the
majority of total cardiac cells are nonmyocytes and
provide structural support (19–21); we thus reasoned
that addition of CDCs might enhance NRVM viability
and/or modulate EECT conduction properties.
To this end, CDCs were bound to CD105-
conjugated microspheres and mixed with NRVMsbound to gamma-sarcoglycan–conjugated micro-
spheres. Electron micrographs revealed that EECTs
constructed with either 2% or 10% CDCs (EECT-C2 or
EECT-C10, respectively) exhibited substantially more
extracellular matrix than EECTs (Figure 4A). EECT-
C10 demonstrated a high degree of Cx43-mediated
gap junction coupling at cell–cell borders (yellow ar-
rowheads, Figure 4B) and higher cell viability
(Figure 4C) than EECTs. Measurements of CV by using
optical mapping indicated that NRVM-only EECTs
conduct at a highly variable velocity of 21.9  19 cm/s
(n ¼ 4). Addition of either 2% or 10% CDCs decreased
FIGURE 4 Addition of 10% CDCs to EECT (EECT-C10) Enhances Structural Integrity
and Improves Viability of EECT in Culture
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(A) Electron microscopy images of EECT (left) and EECT-C10 (right). (B) Immunohisto-
chemistry of EECT (left) and EECT-C10 (right). Green: microspheres; red: sarcomeric actin;
white: connexin 43; blue: 40,6-diamidino-2-phenylindole (DAPI) nuclei. (C) Representative
images of ethidium homodimer staining of EECT and EECT-C10 (left) and quantiﬁcation of
percent live cells (right). (D) Addition of cardiosphere-derived cells (CDCs) to EECT results
in less variability in conduction velocity. In each experimental group, n ¼ 3 biological
replicates. Error bars represent SDs. *p < 0.05 according to 2-way analysis of variance.
Abbreviation as in Figure 2.
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2580the mean CVs (11.1  7 cm/s and 8.7  5 cm/s,
respectively). This ﬁnding is not surprising; CDCs can
couple to NRVMs and other CDCs via gap junctions
(10) but are themselves inexcitable, acting as elec-
trical sinks. More importantly, EECT-C2 and EECT-
C10 exhibited substantially more consistent CV
measurements, with almost 3-fold lower SDs
(Figure 4D). The uniformly lower CVs also render
EECT-C2 and EECT-C10 as favorable AV node surro-
gates, avoiding complications associated with rapidly
conducting accessory pathways (22). These ﬁndings
indicate that the addition of CDCs to EECTs renders
the construct more consistent in structure and
function.
EECT-C RE-ESTABLISHES CONDUCTION FROM THE
ATRIA TO THE VENTRICLES IN A MODEL OF COMPLETE
HEART BLOCK. We tested the ability of EECT-C to
function in the intact heart in a rat model of com-
plete heart block. We sought to ﬁrst create an
accessory tract for conduction between the atria and
the ventricles by using EECT-C and then to verify
that the EECT could sustain conduction upon sup-
pression of the AV node. For these experiments, we
constructed EECT-C10 on a mesh of 30-mm pore size;
we then implanted it by afﬁxing 1 end of the mesh
onto the right atrium and the other end onto the
anterior surface of the right ventricle of the adult rat
heart by using ﬁbrin glue. Surface electrocardio-
grams of EECT-C10–implanted animals 72 h later
showed an increase in QRS interval duration com-
pared with nonimplanted control rats (15.8  0.4 ms
vs. 12.8  0.3 ms; p < 0.05 [n ¼ 3 each group])
(Figure 5A). This outcome veriﬁes creation of a
functional accessory tract, as in Wolff-Parkinson-
White syndrome (23), albeit without accelerated AV
conduction (no signiﬁcant differences in PR interval
duration) (Figure 5B).
After in vivo electrocardiogram recordings, hearts
were explanted and ﬁxed with retrograde perfusion
for recording of surface EGMs (n ¼ 2). Infusion of
methacholine created complete heart block and
slowed the sinus rate (prolongation of A-A interval),
leading to sinus arrest (top panel, Figure 5C). To test
conduction via the EECT-C10 upon methacholine-
induced AV block, the right atrium was paced
electrically, leading to faithful 1:1 capture of the ven-
tricles, as demonstrated by the presence of a ventric-
ular EGM (V) following each atrial EGM (A) and the
atrial pacing deﬂection (P) (bottom panel, Figure 5C).
To conﬁrm that the recorded conduction was in-
deed through the EECT, recordings were repeated
after mechanical disruption of the implanted EECT.
No evidence of ventricular activity was seen after
FIGURE 5 Restoration of AV Block by In Vivo Implantation of EECT
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Recording during ventricular pacing (P) conﬁrms ventricular depolarization (V), verifying
viability of the ventricular myocardium (bottom panel). ECG ¼ electrocardiography; other
abbreviation as in Figures 2 and 4.
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2581EECT removal (top panel, Figure 5D). Viability of
the ventricular myocardium was veriﬁed by the ability
to capture the ventricle with a pacing electrode (bot-
tom panel, Figure 5D). Taken together, our data
show that EECT can support functional A-V conduc-
tion in the intact heart in a model of complete heart
block.
IN VIVO INTEGRATION OF EECT-C THROUGH GAP
JUNCTIONS. Integration of EECT-C to the recipient
myocardium was assessed by immunohistochemistry
of EECT-C–transplanted hearts. Before implantation,
EECT-C was transduced with adenovirus encoding
GFP to distinguish between transplanted cells and
recipient myocardium. Images reveal plentiful Cx43
(white arrows) at the boundary between the EECT-C
and the epicardium (Figure 6). Taken together, the
in vitro and in vivo functional and immunohisto-
chemistry data support the notion that the functional
A-V conduction by EECT-C is mediated by electrical
coupling through Cx43 gap junctions. Nevertheless,
we cannot conclusively rule out the possibility that
the coupling is at least partly mechanical (24,25).
DISCUSSION
Current therapies for myocardial conduction blocks
depend on electronic devices to deliver electrical
pulses downstream of the region of the block (26).
Although effective, it would be desirable to restore
conduction or bypass areas of slow conduction by
regenerating injured myocardium or by implanting an
artiﬁcial conduction tract. As an alternative to devices
and ablative therapies, we engineered de novo elec-
trical conduction tracts capable of bridging myocar-
dial regions of slow conduction or conduction block
(Central Illustration).
The ability of isolated ventricular myocytes in
culture to spontaneously organize into 3-dimensional
structures has long been recognized (27). Moreover, a
number of 3-dimensional tissue culture techniques
were developed as biological systems for studying
cell–cell interactions, electrical coupling, and extra-
cellular matrix interactions (28–30). Various scaffold-
based approaches using different polymers have been
utilized. The ability of skeletal myoblast–based tissue
constructs to restore AV conduction in the rat heart
was ﬁrst described by Choi et al. (31). Using a silicone
cast, the investigators fabricated small tissue con-
structs made from a myoblast Matrigel-based solution
that were subsequently transplanted into the rat
heart (31,32). In addition, Kirkton and Bursac (33)
engineered 3-dimensional cardiac tissue cords con-
sisting of NRVMs and gene-modiﬁed HEK293 cells.
Although the use of transformed HEK293 cellsdiminished the immediate therapeutic potential of
these constructs, gap junctional modiﬁcation of the
HEK293 cells changed the tissue construct’s conduc-
tion properties in a predictable manner, providing an
in vitro platform for studying cardiac conduction
properties.
Our approach used a magnetic ﬁeld to pattern an
EECT composed of paramagnetic microspheres
coated with cell-speciﬁc antibodies. As we showed
with NRVMs and cardiac stromal cells, the ﬂexibility
FIGURE 6 EECT-C Integration With the Recipient Myocardium
Immunohistochemistry of rat myocardium transplanted with EECT-C demonstrates connexin 43 (Cx43)-mediated gap junctions between the recipient myocardium and
EECT-C. (A) Green: paramagnetic microspheres, manufactured to be green ﬂuorescent, as well as NRVMs and CDCs transduced with an adenovirus-encoding green
ﬂuorescent protein (GFP) before implantation; gray: Cx43; red: a-sarcomeric actinin (SA). Bottom right: merged image of GFP, a-SA, and Cx43. (B) Enlargement,
demonstrating the presence of Cx43 (white arrows) between EECT-C and the recipient myocardium. Abbreviations as in Figures 1, 2, and 4.
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provides a generalizable platform to engineer EECTs
with speciﬁc electrophysiological and/or structural
properties. Afﬁnity binding between paramagnetic
beads and ventricular myocytes was mediated by
gamma-sarcoglycan, a surface antigen robustly
expressed on cardiomyocytes, including those of
human origin (34,35). Thus, although we did not test
the theory here, we anticipate that EECTs constructed
with human pluripotent stem cell–derived car-
diomyocytes would exhibit similar functionality as
those constructed with NRVMs. The addition of car-
diac stromal cells increased the structural integrity of
the EECTs and yielded more consistent conduction
properties. Our data demonstrate the ability of the 3-
dimensional tissue structure to restore cardiac elec-
trical conduction in an in vitro model of conduction
block and by implanting a pre-formed EECT-C, in vivo
followed by in vivo and ex vivo electrophysiological
recordings.
Downstream of the AV node, the cardiac conduc-
tion system is electrically insulated, preventing
electrical propagation from dissipating laterally into
the surrounding myocardium (36,37). Likewise, end-to-end electrical propagation along the run of the
EECT without lateral ﬂux would be desirable to
maximize signal ﬁdelity and help overcome imped-
ance mismatch. Our data showed that the EECT con-
structs transplanted in vivo faithfully relayed atrial
activation to the ventricle (Figure 5), indicating that
lateral “signal loss” was insigniﬁcant. Only the ter-
minal ends of the EECT were ﬁbrin-glued to the
myocardium; physical adhesions of the EECT else-
where may eventually form. Complete electrical
insulation of EECT may be challenging because acel-
lular structures such as microtubules can mediate
electrical coupling (38). Nonetheless, our approach
to tissue patterning with paramagnetism and care-
fully chosen cell surface antigens is amenable to
creating insulating layers (should such insulation
be required) composed of poorly coupled cells, such
as dermal ﬁbroblasts (39) above and beneath the
EECTs.
Other than the use of ﬁbrin glue, no treatment was
performed to attach the EECT onto the epicardial
surface. Fibrin glue provides scaffolding for cardiac
tissue engraftment (40), promotes angiogenesis (41),
and mediates nerve regeneration by providing a
CENTRAL ILLUSTRATION Implantation of EECT Restores AV Conduction in Complete Heart Block
Normal conduction (left panel) initiated in the right atrium (P waves) travels across the atrioventricular (AV) node to the ventricles (QRS complexes). In AV block
(central panel), atrial conduction (P waves) cannot reach the ventricular myocardium (absence of QRS complexes). Implantation of EECT (right panel) restores AV
conduction in complete heart block.
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2583favorable matrix microenvironment (42). Because
the EECT ends were afﬁxed to the myocardium at
the time of surgery, and Cxs turn over rapidly (1.5 to
5 h) (11,12), a 3-day window would be sufﬁcient
for establishing gap junctional and/or acellular elec-
trical coupling (38) of the EECT termini to the
myocardium. The presence of Cxs at the border be-
tween the EECT-C and the epicardium 3 days after
EECT-C transplantation in vivo further supports
electrical coupling of EECT-C to the host myocar-
dium, although a role for mechanotransduction
cannot be excluded (24,25).
Spontaneous contraction of the EECT (Online
Video 1) arises from occasional self-excitability of
some NRVMs, driving contraction of the entire
construct, as we observed in the NRVM monolayers
(17). The rate of these occasional contractions is much
lower (w100 beats/min) than the sinus rate of the rat
(w320 beats/min). Thus, sinus rhythm is expected to
entrain spontaneous contraction of the EECT-C upon
implantation in vivo. The EECT is optically thin, with
no more than w5 layers of cells in its short axis.
Although we did not directly examine the long-termviability of the EETCs, such thin structures are ex-
pected to remain viable via soluble gas exchange
without dedicated vasculature. Multiple lines of evi-
dence support this notion: 1) myoglobin-facilitated
oxygen diffusion mechanisms are sufﬁcient to
oxygenate the rat myocardium when cellular oxygen
falls low (43); and 2) diffusion coefﬁcients of oxygen
in muscle ﬁbers (1.1  104 to 4  108 cm2/s) (44,45)
are sufﬁcient to cover the cross-sectional dimensions
of the EECT.
STUDY LIMITATIONS. As electrical conduction prop-
agates along the EECT, it encounters a highly hyper-
polarizing, electrical sink at the EECT–ventricular
myocardium interface. This is akin to the source–sink
mismatch in the sinoatrial node surrounded by the
hyperpolarizing atrial myocardium. The sinoatrial
node solves this problem by populating its pace-
maker cells with Cx45-expressing ﬁbroblasts, thereby
raising the input resistance (46). Similarly, incorpo-
rating relatively uncoupled CDCs (10) into EECTs
should increase the input resistance, protecting the
electrical source carried along the EECT-C10 from
dissipation at the ventricular myocardium. Further
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Although electronic pacemakers are presently used to
manage patients with symptomatic bradycardia,
engineered electrical conduction tracts could poten-
tially create a substrate for restoring atrioventricular
synchrony in those with atrioventricular nodal block.
TRANSLATIONAL OUTLOOK: Reﬁned, less inva-
sive delivery methods are needed to enable trans-
plantation of engineered electrical conduction tracts
capable of bypassing areas of conduction block,
thereby restoring conduction at various levels of the
cardiac conduction system and reducing the need for
artiﬁcial electronic pacemakers.
Cingolani et al. J A C C V O L . 6 4 , N O . 2 4 , 2 0 1 4
Engineered Conduction Tract Restores Conduction Block D E C E M B E R 2 3 , 2 0 1 4 : 2 5 7 5 – 8 5
2584in vivo studies are warranted to test this notion. The
low number of animals for the in vivo proof of
concept experiments is a limitation of the present
study.
The epicardial positioning of EECTs in the present
study was purposely extravascular. Nevertheless,
the paramagnetic microspheres used in this study
were 8 mm in diameter, which may cause issues if
released into the circulation. Although unlikely, this
complication can be avoided in future constructs, as
the present approach is amenable to smaller or
biodegradable spheres, both of which are available
commercially.
CONCLUSIONS
This proof of concept study showed that EECTs can
re-establish cardiac electrical conduction between
isolated regions of 2-dimensional cardiac tissue, as
well as in the whole heart. Delivery and trans-
plantation techniques need to be reﬁned before
translating this approach to large animal models. This
technology could also be exploited for alternatives
to open chest implantation, such as in situ EECT
formation using transcutaneous or transesophageal
electromagnetic probes to conglomerate tagged cells.
The present approach is highly generalizable, offering
a novel platform to engineer biocompatible materials
for relaying electrical signals. A similar approach
could be used, in principle, to bridge interruptedneural circuits in stroke, nerve, or spinal cord
injuries.
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